Tumor proportion in colon cancer: results from a semiautomatic image analysis approach

Benedikt Martin1 · Bettina Monika Banner1 · Eva-Maria Schäfer1 · Patrick Mayr1,2 · Matthias Anthuber3 · Gerhard Schenkirsch4 · Bruno Märkl1

Received: 20 September 2019 / Revised: 13 January 2020 / Accepted: 27 January 2020 © The Author(s) 2021

Abstract
The tumor stroma ratio (TSR) is a promising prognostic biomarker in colon cancer, which could provide additional risk stratification for therapy adaption. The objective of our study was the investigation of the prognostic significance of TSR at different tumor sites in a simple semiautomatic approach with the open-source program ImageJ. We investigated 206 pT3 and pT4 adenocarcinomas of no special type. According to our established thresholds, 31 tumors (15%) were classified as low tumor proportion (TP) (≤ 15% TP), 42 tumors (20%) were classified as high TP (≥ 54% TP), and 133 tumors (65%) were classified as medium TP. High and low TP were associated with an adverse overall survival in comparison to medium TP (p = 0.001 and p = 0.03). Furthermore, the TP was an independent risk factor of occurrence of distant metastasis next to T status, microsatellite status, and tumor budding. The 5-year survival rate was 49% in patients with high TP, 48% in patients with low TP, and 68% in patients with medium TP (p = 0.042, n = 160). Patients with a high TP had less often tumor budding (p = 0.012), lymphovascular invasion (p = 0.049), and less harvested lymph nodes (p = 0.042) in comparison to low TP tumors. The results provide first evidence that a high tumor proportion/low stroma proportion is also associated with an adverse prognosis and that this subgroup might be difficult to identify with other classical histopathologic characteristics that are linked to an adverse prognosis.

Keywords Colon cancer · Tumor stroma ratio · Biomarker · ImageJ

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00428-020-02764-1) contains supplementary material, which is available to authorized users.

Benedikt Martin
benedikt.martin@uk-augsburg.de

1 Institute of Pathology and Molecular Diagnostics, University Hospital Augsburg, Augsburg, Germany
2 Department of Radiooncology, University Hospital Augsburg, Augsburg, Germany
3 Department of Visceral Surgery, University Hospital Augsburg, Augsburg, Germany
4 Tumor Data Management, University Hospital Augsburg, Augsburg, Germany

Published online: 19 February 2020
Introduction

“Over 1.8 million new colorectal cancer cases and 881,000 deaths are estimated to occur in 2018, accounting for about 1 in 10 cancer cases and deaths. Overall, colorectal cancer ranks third in terms of incidence but second in terms of mortality” [1]. These estimates illustrate that colorectal cancer is a serious, worldwide public health problem. Today, tumor-node-metastasis (TNM) staging of the American Joint Committee on Cancer (AJCC) is still considered the gold standard for staging. Irrespective thereof, tumor stroma ratio (TSR) is a promising new prognostic biomarker in colon cancer, which could provide additional risk stratification for therapy adaptation. In colon cancer, studies were able to show that a high proportion of intratumoral stromal tissue is associated with a worse prognosis [2–7]. The prognostic value of the tumor stroma has also been shown in breast, ovarian, cervical, gastric, and esophageal cancer [8–13]. The complete biological role of stroma is not fully understood, yet. It is well known that the stroma has an important role for the supply of the tumor and the formation of blood vessels and that the stroma can promote tumorigenesis and metastasis [14–17].

The objective of this study was the investigation of the prognostic significance of stroma/tumor proportion at different tumor sites of colon adenocarcinomas (pT3/4) of no special type with a simple semiautomatic approach with the open-source program ImageJ [22].

Materials and methods

Case collective

We retrospectively evaluated 215 patients with colon adenocarcinomas of no special type, pT3/4, N±, M0, R0, and at least 3-month survival after surgery. All patients underwent surgery at the University Hospital Augsburg between January 2002 and December 2011, and none of the patients had received preoperative chemo- or radiotherapy. We excluded 9 patients because of insufficient tumor tissue or insufficient immunohistochemical staining result (e.g., because of improper fixation) from further analysis. Location: we defined right-sided tumors from oral to the left colonic flexure (excluded) and left-sided tumors from the left colonic flexure (included) to aboral. The evaluation of lymphatic vessel and venous invasion were performed in each case on all tumor H&E slides. Follow-up data were provided by the Tumor Data Management of the University Hospital Augsburg and complemented with data of the patient files. Tumor budding was graded according to ITBCC, and in each case, the consensus rating was used to define the budding grade, as recently published [23, 24]. The study protocol was approved by the Institutional Review Board of University Hospital Augsburg, Germany.

Assessment of tumor and stroma proportion

In each case, three regions were selected for the assessment of the tumor proportion (TP)/stroma proportion (SP). These were (1) FroTP, defined as the region with the deepest infiltration, measured directly at the invasive front; (2) minimal tumor proportion (MinTP), defined as the region suspected to have the highest SP/lowest TP on the slide; and (3) maximum tumor proportion (MaxTP), defined as the region suspected to have the lowest SP/highest TP. In each case, one representative H&E section (and a corresponding cytokeratin staining), which did show the deepest TNM relevant infiltration depth, was used by Be. Ba. or in difficult cases by cooperation of Be. Ba. and Be. Ma. for selection of the regions.

The workflow was the following: After an overview of the H&E slide, we selected the best fitting regions to the abovementioned definitions with exclusion of areas containing significant amount of blood vessels, necrosis, abscesses, mucinous areas, or large glandular lumen. Glandular tumor lumen could not be ignored from analysis because of the subsequent digital workflow (binary coding). Lumen was assigned to tumor proportion. The TP and SP were assessed in a field of 3.58 mm², but, differing from the recommendations from van Pelt et al., we used a rectangular selection (side lengths, 2.18 mm and 1.64 mm; field size, 3.58 mm²) instead of a classical round microscope selection due to usage of a camera [11]. We selected only regions in which tumor cells were present at all four borders of the image field. The selection process of each region was performed using a microscope (Olympus, BX43F, Tokyo, Japan) with attached camera with connection to a computer (ProgRes® Speed XCore5 with combined software: Capture Pro 2.9.0.1). Digital images were captured (×4 objective) of the immunohistochemical stained slide against a cytokeratin that highlighted the tumor tissue. If a histochemical stained slide, corresponding to the selected H&E slide, was already available, we used that one. If not, we prepared a cytokeratin AE1/AE3 immunostaining according to our routine protocol (antibody, cell marques™, monoclonal mouse antibody; dilution 1:500; DAB Opti View IHC Detection Kit; immunostainer, Roche Benchmark Ultra). Subsequently, the open-source image processing software ImageJ (Version 1.48 v) was used for TP and SP assessment [22]. We used the function principle that
immunohistochemically marked brown dark tumor tissue can be differentiated via binary coding from the surrounding light stroma tissue (Fig. 1). After binary coding of the taken images and eliminating the lumen of the tumor cells (run (“make binary”); run (“fill holes”), Be. Ba. reviewed the result, manually improving the result if necessary (especially, filled up gaps that were not recognized by the algorithm). After calibration, the images were measured (run (analyze particles)). To exclude scoring of dust particles, we only scored particles of at least 0.00023 mm² in size. We defined tumor proportion as the following: sum of all tumor areas/3.58 mm². We defined stroma proportion as the following: (3.58 mm² - sum of all tumor areas)/3.58 mm².

**Statistical analysis**

All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS software version 24.0 (SPSS, Chicago, IL, USA)). The database was partitioned into an exploration and validation set for cutoff determination. The exploration set (n = 104) included all cases with odd study numbers of the original set (before exclusion of patients), and the validation set included all cases with even study numbers (n = 102) of the original set. The chi-square test was applied for comparisons of categorical data. The Mann-Whitney U test was applied for comparisons between continuous and ordinal variables between two groups. The Kruskal-Wallis test was applied for comparisons between continuous and ordinal variables for more than two groups. Univariate event/survival analyses were done according to the Kaplan-Meier method (log-rank test) for assessment of statistical significance. Cox regression analysis (forward, likelihood ratio) was performed to investigate the independence of univariate-identified risk factors. Results were considered statistically significant if p < 0.05. Continuous variables were demonstrated as mean ± standard deviation (SD), if not otherwise specified.

**Results**

**Patients and scoring results**

The mean age of the 206 patients at date of diagnosis was 70.0 ± 11.3 years, the mean follow-up time was 5.3 ± 3.5 years, and 85 (41%) patients died during the follow-up period. The detailed clinicopathological characteristics are shown in Table 1.

The mean/median TP was 36%/36% at FroTP, 32%/31% at MinTP, and 71%/73% at MaxTP, respectively (Table 2). The MinTP was assumed to be in the same region as the FroTP in 161 tumors (78%).

**Determination of cutoff values**

The stroma high group included 76% (FroTP) and 86% (MinTP) of the cases according to a cutoff at 50%. As the
tumor proportion in our study, and consequently the corresponding group sizes, differed considerably (if the classical cutoff was applied) from published literature (discussed later), we divided our population into an exploration and validation set for cutoff determination. We used a receiver operating characteristic (ROC) curve approach to determine the optimal cutoff point for the prediction of distant metastasis (Fig. 2a, ROC curve exploration set). As the ROC curve of the exploration set of FroTP has two contrary deviations from the diagonal, we determined two cutoff values. We determined the

| Variable                                | n = 206 | High TP (n = 42) | Medium TP (n = 133) | Low TP (n = 31) | p value |
|-----------------------------------------|---------|------------------|---------------------|----------------|---------|
| Mean age (years)                        | 70.0 ± 11.3 | 73.9 ± 12.2 | 68.6 ± 11.4 | 70.8 ± 8.3 | 0.013 |
| Mean follow-up (years)                  | 5.3 ± 3.5 | 4.8 ± 3.5 | 5.7 ± 3.6 | 4.4 ± 2.7 | 0.139 |
| Mean lymph node harvest (n)             | 23 ± 13 | 19 ± 8 | 24 ± 14 | 26 ± 15 | 0.084 |
| Positive lymph nodes (n)                | 1.2 ± 2.3 | 0.9 ± 1.9 | 1.1 ± 2.3 | 1.7 ± 2.4 | 0.485 |

| Sex                                      |         |                  |                    |               |         |
|------------------------------------------|---------|------------------|-------------------|---------------|---------|
| Female                                   | 88      | 43%              | 40%               | 44%           | 42%     |
| Male                                     | 118     | 57%              | 60%               | 56%           | 58%     |

| T status                                 |         |                  |                    |               |         |
|------------------------------------------|---------|------------------|-------------------|---------------|---------|
| pT3                                      | 180     | 87%              | 88%               | 87%           | 98%     |
| pT4                                      | 26      | 13%              | 12%               | 13%           | 9%      |

| Nodal status                             |         |                  |                    |               |         |
|------------------------------------------|---------|------------------|-------------------|---------------|---------|
| Negative                                 | 128     | 62%              | 67%               | 62%           | 58%     |
| Positive                                 | 78      | 38%              | 33%               | 38%           | 42%     |

| Vascular invasion                        |         |                  |                    |               |         |
|------------------------------------------|---------|------------------|-------------------|---------------|---------|
| Negative                                 | 186     | 90%              | 93%               | 89%           | 94%     |
| Positive                                 | 20      | 10%              | 7%                | 11%           | 6%      |

| Lymphovascular invasion                  |         |                  |                    |               |         |
|------------------------------------------|---------|------------------|-------------------|---------------|---------|
| Negative                                 | 171     | 83%              | 95%               | 80%           | 81%     |
| Positive                                 | 35      | 17%              | 5%                | 20%           | 19%     |

| Grading                                  |         |                  |                    |               |         |
|------------------------------------------|---------|------------------|-------------------|---------------|---------|
| Low grade                                | 141     | 68%              | 69%               | 71%           | 58%     |
| High grade                               | 65      | 32%              | 31%               | 29%           | 42%     |

| Tumor budding                            |         |                  |                    |               |         |
|------------------------------------------|---------|------------------|-------------------|---------------|---------|
| Bd 1                                     | 168     | 82%              | 90%               | 82%           | 68%     |
| Bd 2                                     | 25      | 12%              | 7%                | 14%           | 13%     |
| Bd 3                                     | 13      | 6%               | 2%                | 5%            | 19%     |

| Location                                 |         |                  |                    |               |         |
|------------------------------------------|---------|------------------|-------------------|---------------|---------|
| Right                                    | 127     | 62%              | 62%               | 62%           | 61%     |
| Left                                     | 79      | 38%              | 38%               | 38%           | 39%     |

| Microsatellite status                    |         |                  |                    |               |         |
|------------------------------------------|---------|------------------|-------------------|---------------|---------|
| MSS                                      | 180     | 87%              | 90%               | 84%           | 97%     |
| MSI                                      | 26      | 13%              | 10%               | 16%           | 3%      |

| Distant metastasis                       |         |                  |                    |               |         |
|------------------------------------------|---------|------------------|-------------------|---------------|---------|
| No                                       | 165     | 80%              | 67%               | 87%           | 68%     |
| Yes                                      | 41      | 20%              | 33%               | 13%           | 32%     |

| Death                                    |         |                  |                    |               |         |
|------------------------------------------|---------|------------------|-------------------|---------------|---------|
| No                                       | 121     | 59%              | 38%               | 67%           | 52%     |
| Death                                    | 85      | 41%              | 62%               | 33%           | 48%     |

| 5-year survival (n = 160)                |         |                  |                    |               |         |
|------------------------------------------|---------|------------------|-------------------|---------------|---------|
| Survived                                 | 97      | 61%              | 49%               | 68%           | 48%     |
| Death                                    | 63      | 39%              | 51%               | 32%           | 52%     |

p values are shown for difference between the low, medium, and high tumor proportion group, classified by cutoffs at FroTP

MSI microsatellite instable, MSS microsatellite stable
cutoffs that resulted in the lowest $p$ value in the exploration set according to the occurrence of distant metastasis by testing and adjusting. Additionally, we performed subsequently ROC analyses of MinTP and MaxTP. The analysis of MaxTP did not reveal a relevant prognostic result (ROC – curve MaxTP in supplement (S1)), and the analysis of MinTP was inferior to the analysis of FroTP (ROC – curve MinTP in supplement (S2)) but showed similar results according to the values of the cutoffs at FroTP.

### Prognostic analyses

The established cutoff values at FroTP are low TP $\leq 15\%$ TP; medium TP, $15\% < TP < 54\%$; and high TP $\geq 54\%$ TP. According to these thresholds, 42 tumors (20%) were classified as high TP, 31 tumors (15%) were classified as low TP, and 133 tumors (65%) were classified as medium TP (FroTP). An overview of the mean tumor proportions in the different groups is given in Table 2. In the exploration set, a low TP as well as a high TP was associated with occurrence of distant metastasis in comparison to medium TP ($p = 0.009$ and $p = 0.015$, Fig. 2b). In the validation set, a high TP was also associated with occurrence of distant metastasis and worse overall survival in comparison to the medium TP group ($p = 0.021$ and $p = 0.006$). A low TP was associated with occurrence of distant metastasis, and the $p$ value did show a trend towards significance according to an adverse overall survival in comparison to the medium TP group ($p = 0.037$ and $p = 0.094$, Fig. 3b).

### Multivariate Cox regression

Additionally, we performed a multivariate Cox regression (forward, likelihood ratio) for the occurrence of distant metastasis including the following risk factors (all variables with a

| Variable     | All ($n=206$) | High TP ($n=42$) | Medium TP ($n=133$) | Low TP ($n=31$) | $p$ value |
|--------------|---------------|------------------|---------------------|-----------------|-----------|
| Mean FroTP   | 36 ± 18       | 62 ± 7           | 34 ± 11             | 11 ± 8          | < 0.001   |
| Mean MinTP   | 32 ± 16       | 49 ± 17          | 32 ± 10             | 11 ± 3          | < 0.001   |
| Mean MaxTP   | 71 ± 13       | 77 ± 9           | 70 ± 13             | 65 ± 15         | 0.001     |

$p$ values are shown for difference between the low, medium, and high tumor proportion group, classified by cutoffs at FroTP.

A further Kaplan-Meier analysis in the overall patient population showed a significant adverse overall survival for patients with a high and low TP in comparison to patients with medium TP ($p = 0.001$ high TP; $p = 0.03$ low TP, Fig. 3a). The 5-year survival rate was 49% in patients with high TP, 48% in patients with low TP, and 68% in patients with medium TP ($p = 0.042$, $n = 160$).

We applied the established cutoffs at FroTP region also at the MinTP region. Thereby, in the overall population ($n = 206$), 147 patients (71%) were assigned to medium TP group, 25 patients (12%) to the high TP group, and 34 patients (17%) to the low TP group. A high TP was associated with occurrence of distant metastasis and worse overall survival in comparison to the medium TP group ($p = 0.021$ and $p = 0.006$). A low TP was associated with occurrence of distant metastasis, and the $p$ value did show a trend towards significance according to an adverse overall survival in comparison to the medium TP group ($p = 0.008$ and $p = 0.094$, Fig. 3b).

**Table 2** Overview of the tumor proportion in the different regions

**Fig. 2** a ROC curve for the occurrence of distant metastasis in the exploration set. b Kaplan-Meier curves for the occurrence of distant metastasis in the exploration set (high versus medium tumor proportion $p = 0.015$; low versus medium tumor proportion $p = 0.009$). c Kaplan-Meier curves for the occurrence of distant metastasis in the validation set (high versus medium tumor proportion $p = 0.037$; low versus medium tumor proportion $p = 0.105$).
significance level $p \leq 0.1$ in univariate analyses): age ($\geq 70$ years versus $< 70$ years), pT, pN (positive versus negative), lymphovascular invasion, sidedness, microsatellite status, tumor budding, FroTP (defined as categorical variable), and MinTP (defined as categorical variable). T status, microsatellite status, tumor budding, as well as FroTP were integrated into the model as independent risk factors. The hazard ratios for the low and high TP groups (FroTP) were $2.7 (1.2$–$6.0$, $p = 0.016$) and $3.2 (1.6$–$6.7$, $p = 0.001$) (Table 3).

Furthermore, we performed another multivariate Cox regression (forward, likelihood ratio) for overall survival including factors with a significance level $p \leq 0.1$ in univariate analyses. We excluded distant metastasis as risk factor from this analysis, as it indicates tumor progression during follow-up. In this model, the FroTP, as well as the T status, and the age were independent risk factors (Table 3).

**Characteristics of the different groups**

There were significant differences between the three groups according to the frequency of tumor budding and the age of the patients (see Table 1). A low TP was associated to tumor budding ($p = 0.012$ low TP vs. high TP; $p = 0.046$ low TP vs. medium TP) and a higher lymph node harvest ($p = 0.042$ low TP vs. high TP; $p = 0.480$ for low TP vs. medium TP). A high TP was associated to the absence of tumor budding ($p = 0.012$ high TP vs. low TP; $p = 0.192$ high TP vs. medium TP), lymphovascular invasion ($p = 0.049$ high TP vs. low TP; $p = 0.018$ high TP vs. medium TP), and a lower lymph node harvest ($p = 0.042$ high TP vs. low TP; $p = 0.057$ high TP vs. medium TP).

**Discussion**

In this study, we investigated the tumor and stroma proportion in different regions of 206 pT3 and pT4 adenocarcinomas (NOS) of the colon in a semiautomatic image analysis approach. We used the open-source software ImageJ and the principle that immunohistochemically marked tissue can be differentiated via binary coding from surrounding light stroma tissue. We divided our patient population into an exploration and validation set for cutoff determination. In the validation set, we could confirm that a high TP/low SP ($\geq 54\%$ TP $p = 0.037$) is associated with occurrence of distant metastasis. In the overall population, a high TP at FroTP was significantly associated with a worse overall survival and lower 5-year survival rate (see Fig. 3 and Table 1). Additionally, a multivariate Cox regression did show that a high TP is an independent risk factor for occurrence of distant metastasis beside the T status, microsatellite status, and the tumor budding grade. The hazard ratio of patients with high TP was $3.2 (1.6$–$6.7)$ in comparison to medium TP ($p = 0.001$). These findings are quite surprising, because, so far, only a low TP/high SP has been linked to a worse prognosis [14]. In this study, a low TP/high SP ($\leq 15\%$ TP) at FroTP was also associated with a worse
overall survival ($p = 0.03$ for low TP vs medium TP, Fig. 3), and the 5-year survival rate was lower than in the medium TP group ($p = 0.042$). The results of the prognostic impact of the MinTP region seem to be similar but all in all a bit inferior than at FroTP. We could not find a relevant prognostic impact of the MaxTP region (ROC curve supplement), which emphasizes the relevance of the selected region for the assessment. The different mean TPs in the MinTP (32%), FroTP (36%), and MaxTP (71%) show the extent of tumor stroma heterogeneity. In literature, different tumor regions have been investigated according to their prognostic value. Van Pelt et al. recommend that the region with the highest stroma proportion on the slide of the most invasive part should be decisive [11]. Besides that, other groups could show that a high stroma content of the “whole” tumor, as well as at the luminal surface, is prognostic [5, 20]. The luminal region has the advantage that biopsies could be scored, but all in all, the recommendations of van Pelt et al. seem to be the most promising for a near-term implementation as an easy diagnostic tool [25].

Interestingly, high TP tumors miss conventional adverse histological features. These tumors had a low proportion of tumor budding ($p = 0.012$ for low TP and $p = 0.192$ for medium TP) and a low proportion of lymphovascular invasion ($p = 0.049$ for low TP and $p = 0.018$ for medium TP). Furthermore, less lymph nodes have been harvested in these tumors ($p = 0.042$ for low TP and $p = 0.057$ for medium TP). Assuming that the lymph node count is a surrogate indicator of the immunological response to the tumor, one might speculate that

### Table 3  $p$ values and hazard ratios for univariate and multivariate analyses

| Variable                          | Univariate analyses | Multivariate Cox regression analyses |
|-----------------------------------|---------------------|--------------------------------------|
|                                   | Distant metastasis, $n = 206$ | Overall survival, $n = 206$ | 5-year survival, $n = 160$ | Distant metastasis, hazard ratio, and 95% CI | P value | Overall survival, hazard ratio, and 95% CI | p value |
| Sex                               | 0.18 0.66 0.639 |                           |                           |                         | 0.17     | 2.2 (1.4–3.6) 0.001 |
| Mean age (years)                  | 0.096 < 0.001 0.002 |                           |                           |                         | 0.69     |                           |
| > = 70 years                      | 0.14 0.24 0.573 |                           |                           |                         | 0.14     |                           |
| Mean lymph node harvest           | <0.001 0.018 0.012 |                           |                           |                         | 0.048    | 0.071                      |
| >= 23 lymph nodes                 | 0.02 0.34 0.179 | 4.7 (2.3–9.7) < 0.001 2.2 (1.2–3.9) | 0.01                       |
| T3                                |                           |                         |                           |                         | 0.071    | 0.14                      |
| T4                                | 0.06 0.25 0.468 |                           |                           |                         | 0.001    |                           |
| Nodal status (+ vs. -)            | 0.19 0.49 0.64 |                           |                           |                         | 0.001    |                           |
| Vascular invasion                 |                           |                         |                           |                         | 0.001    |                           |
| Lymphovascular invasion           | 0.04 0.39 0.133 |                           |                           |                         | 0.001    |                           |
| Grading                           | 0.34 0.89 0.697 |                           |                           |                         | 0.001    |                           |
| Tumor budding                     | 0.047 0.669 0.598 | 1.6 (1.003–2.4) 0.048 0.23 | 0.69                      |
| Sidedness                         | 0.03 0.23 0.374 |                           |                           |                         | 0.071    | 0.14                      |
| Microsatellite status             | 0.001 0.002 0.042 |                           |                           |                         | 0.071    | 0.14                      |
| MSS                               | 0.12 (0.02–0.92) |                         |                         |                         | 0.04     |                           |
| MSI                               |                           |                         |                           |                         | 0.04     |                           |
| Tumor proportion (FroTP)          | 3.2 (1.6–6.7) | 0.001 2.1 (1.3–3.4) 0.004 | 0.048 0.23 | 0.001 2.1 (1.3–3.4) 0.004 |
| High tumor proportion             |                           |                         |                           |                         | 0.001    | 0.004                      |
| Medium tumor proportion           |                           |                         |                           |                         | 0.001    | 0.004                      |
| Low tumor proportion              | 2.7 (1.2–6.0) |                           | 0.016 2.0 (1.1–3.7) | 0.02 2.0 (1.1–3.7) | 0.02 |
| Tumor proportion (MinTP)          | 0.009 0.01 0.084 | ns 0.016 2.0 (1.1–3.7) | 0.02 2.0 (1.1–3.7) | 0.02 2.0 (1.1–3.7) | 0.02 |
| Distant metastasis                | <0.001 <0.001 | ns ns ns ns | ns ns ns ns | ns ns ns ns | ns ns ns ns |

CI confidence interval, MSI microsatellite instable, MSS microsatellite stable, ns not significant

FroTP region at invasion front with deepest infiltration; MinTP region with suspected lowest tumor proportion
the immunological landscape plays an important role in these cases [26]. Further studies could clarify this relation more closely and potentially identify therapeutic opportunities for this subgroup. Patients with a high TP were significantly older than the rest of the patients (p = 0.004 for medium TP and p = 0.031 for low TP), but the Cox regression analysis did show that the adverse prognostic effects are independent of age. Other significant differences could not be observed (see Table 1). A morphologic reevaluation of the high TP tumors revealed no morphologic characteristics.

There are several critical aspects, which have to be taken into account in interpreting the data of this study. Despite highly significant results, one has to keep in mind that the data is from a single center and the design is retrospective with all the well-known associated drawbacks.

The cutoff determination for TP, for defining this subgroup, has been determined in an exploration and validation set for the occurrence of distant metastasis; however, the survival analyses have been performed in the overall patient population, which consists of the two sets. The presented approach of TP and SP assessment based on binary coding with ImageJ has advantages but also limitations. The presented workflow is not as time and cost-effective as the conventional assessment on H&E. However, the necessary input and resources are limited, as the workflow can be established with basic equipment and only requires an open-source software. After binary coding, the result has to be manually reviewed and if necessary reworked. Two typical causes for rework can be seen in Fig. 1c and j. In Fig. 1j, the binary coding and the “fill the holes” algorithm missed to fill up all holes. Therefore, all lumen had to be stained manually black (Fig. 1b). Comparing Fig. 1b and c shows that a central non-tumor part has been falsely stained black. After drawing a small white connection to the surrounding light stroma area, the area could be correctly recognized (Fig. 1b). Of course, this kind of review and reworking process is a source of interobserver variability, but we consider that of lesser importance because the anti-cytokeratin staining can be used as model. All in all, it has been reported that the reproducibility of TSR scoring is good [11]. Irrespective thereof, we assume that the direct comparability of our results to studies in the existing literature is limited. In comparison to West et al., the median TP was considerably lower (22/26 percentage points in comparison to FroTP/MinTP), and after applying the established cutoff at 50% stroma, a high proportion of patients has been assigned to the high stroma group (76% for FroTP/86% for MinTP) [5]. In most studies, the high SP group included only 20–30% of all tumors [3, 4, 19]. We assume the main reason for the lower TP and higher SP is that we have used an anti-cytokeratin stained slide for the selection of the regions and that we accepted also tumor buds, as part of the tumor, at the borders of the region (Fig. 1). A further factor that influenced the TP/SP is that we were not able to ignore different areas from scoring. Glandular lumen was assessed to the tumor. Therefore, in this study, the TP corresponds to the area that is covered and enclosed by tumor. Small areas with necrotic tissue, smooth muscle tissue, etc., which had to be accepted in some cases after carefully taking all relevant factors (tumor tissue at all four part at the edges, overall appearance of the tumor, etc.) into account, were assigned to stroma proportion. Another reason which might have contributed to the difference in cutoffs in comparison to the literature is that semiquantitative visual estimation appears to underestimate the TSR in high stroma regions [27]. A limiting factor according to the evaluation of lymphatic and vascular invasion is that no mandatory elastica staining was performed.

**Conclusion**

This study demonstrates the feasibility of a semiautomatic image analysis approach for TSR assessment in colon cancer and in accordance with literature, and the results confirm that a high stroma proportion is associated with an adverse prognosis. Beyond that, the results provide first evidence that a low stroma proportion/high tumor proportion might also be an independent risk factor for the occurrence of distant metastasis and a worse overall survival. Furthermore, the results indicate that this subgroup also differs according to the clinicopathological characteristics from other tumors.

**Acknowledgments** We would like to thank Louis Bujnoch for language editing and proofreading.

**Authors’ contributions** All authors revised the article critically, contributed with reflective improvements, and approved the final version. BR. MI., BE. MA., and BE. BA. contributed to the study conception and design. EV. SC., BE. BA., GE. SC., MA. AN., and BE. MA. contributed to the data acquisition. BR. MI., BE. MA., BE. BA., and PA. MA. contributed to the data analysis and interpretation.

**Funding information** Open access funding enabled and organized by Projekt DEAL. We did not receive an external funding for the study.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethical approval** The Institutional Review Board of the Hospital Augsburg reviewed and approved the study protocol.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will...
References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

2. Park JH, Richards CH, McMillan DC, Horgan PG, Roxburgh CS (2014) The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. Ann Oncol 25:644–651. https://doi.org/10.1093/annonc/mdt593

3. Mesker WE, Jungebluth JMC, Szuha K, de Heer P, Morreau H, Tanke HJ, Tollenaar RA (2007) The carcinoma–stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol Off J Int Soc Cell Oncol 29:387–398. https://doi.org/10.1151/2007/175276

4. Mesker WE, Liefers GJ, Jungebluth JM et al (2009) Presence of a high amount of stroma and downregulation of SMAD4 predict worse survival for stage IV colon cancer patients. Cell Oncol 31:169–178. https://doi.org/10.3233/CLO-2009-0478

5. West NP, Dattani M, McShane P, Hutchins G, Grabsch J, Mueller W, Treanor D, Quirke P, Grabsch H (2010) The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients: validation in the VICTOR trial. Ann Oncol 24:179–185. https://doi.org/10.1093/annonc/mds246

6. Hynes SO, Coleman HG, Kelly PJ, Irwin S, O’Neill RF, Gray RT, McGready C, Dunne PD, McQuaid S, James JA, Salto-Tellez M, Loughrey MB (2017) Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colorectal cancer in a large population-based study. Histopathology 71:12–26. https://doi.org/10.1111/his.13181

7. Eriksen AC, Sørensen FB, Lindebjerg J, Hager H, dePont Christensen R, Kjær-Frifeldt S, Hansen TF (2018) The prognostic value of tumour stroma ratio and tumour budding in stage II colon cancer. A nationwide population-based study. Int J Color Dis 33:1115–1124. https://doi.org/10.1007/s00384-018-3076-9

8. Kramer CSH, Vangangelt KMH, van Pelt GW, Dekker TJA, Tollenaar RAEM, Mesker WE (2019) The prognostic value of tumour–stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review. Breast Cancer Res Treat 173:55–64. https://doi.org/10.1007/s10549-018-4987-4

9. Liu J, Liu J, Li J, Chen Y, Guan X, Wu X, Hao C, Sun Y, Wang Y, Wang X (2014) Tumor-stroma ratio is an independent predictor for survival in early cervical carcinoma. Gynecol Oncol 132:81–86. https://doi.org/10.1016/j.ygyno.2013.11.003

10. Courrech Staal EFW, Wouters MJWM, van Sandick JW et al (2010) The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Eur J Cancer Oxf Engl 46:720–728. https://doi.org/10.1016/j.ejca.2009.12.006

11. van Pelt GW, Kjær-Frifeldt S, van Krieken JHJM, al Dieri R, Morreau H, Tollenaar RAEM, Sørensen FB, Mesker WE (2018) Scoring the tumour-stroma ratio in colon cancer: procedure and recommendations. Virchows Arch Int J Pathol 473:405–412. https://doi.org/10.1007/s00428-018-2408-z

12. Aurello P, Berardi G, Giulitti D et al (2017) Tumor-stroma ratio is an independent predictor for overall survival and disease free survival in gastric cancer patients. Surg J R Coll Surg Edinb Irel 15:329–335. https://doi.org/10.1016/j.surge.2017.05.007

13. Freeman MR, Li Q, Chung LWK (2013) Can stroma reaction predict cancer lethality? Clin Cancer Res Off J Am Assoc Cancer Res 19:4905–4907. https://doi.org/10.1158/1078-0432.CCR-13-1694

14. van Pelt GW, Sandberg TP, Morreau H, Gelderblom H, van Krieken J, Tollenaar RAEM, Mesker WE (2018) The tumour-stroma ratio in colon cancer: the biological role and its prognostic impact. Histopathology 73:197–206. https://doi.org/10.1111/his.13489

15. Vermeulen L, de Sousa Melo EF, van der Heijden M et al (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12:468–476. https://doi.org/10.1038/ncb2048

16. Merlos-Suárez A, Barriga FM, Jung P, Iglesias M, Céspedes MV, Rossell D, Sevillano M, Hernando-Mombliona X, da Silva-Diz V, Muñoz P, Clevers H, Sancho E, Manguès R, Battle E (2011) The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 8:511–524. https://doi.org/10.1016/j.stem.2011.02.020

17. Dalerba P, Kalisky T, Sahoo D, Rajendran PS, Rothenberg ME, Leyrat AA, Sim S, Okamoto J, Johnston DM, Qian D, Zabala M, Bueno J, Neff NF, Wang J, Shelton AA, Visser B, Hisamori S, Shimoto Y, van de Wetering M, Clevers H, Clarke MF, Quake SR (2011) Single-cell dissemination of transcriptional heterogeneity in human colon tumors. Nat Biotechnol 29:1120–1127. https://doi.org/10.1038/nbt.2038

18. Quinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, de Sousa É, Melo F, Missiaglia E, Ramay H, Barras D, Hemicisko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Vertamil B, Laders T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorezeni M, Kopezt S, Vermeulen T, Teijpar S (2015) The consensual molecular subtypes of colorectal cancer. Nat Med 21:1350–1356. https://doi.org/10.1038/nm.3967

19. Huibers A, RAEM T, van Pelt GW et al (2013) The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol 24:179–185. https://doi.org/10.1093/annonc/mds246

20. Hutchins GGA, Treanor D, Wright A, Handley K, Magill L, Tinkler-Hundal E, Southward K, Seymour M, Kerr D, Gray R, Quirke P, QUASAR trial collaborators and the UK National Cancer Research Institute Colorectal Cancer Clinical Studies Group (2018) Intratumoral stromal morphometry predicts disease recurrence but not response to 5-fluorouracil-results from the QUASAR trial of colorectal cancer. Histopathology 72:391–404. https://doi.org/10.1111/his.13326

21. Geesink OGF, Baidoshivili A, Klaase JM, Ehteshami Bejnordi B, Litjens GJS, van Pelt G, Mesker WE, Nagtegaal ID, Ciompi F, van der Laak J (2019) Computer aided quantification of intratumoral stroma yields an independent prognosticator in rectal cancer. Cell Oncol Dordr 42:331–341. https://doi.org/10.1007/s13402-019-00429-z

22. Schneider CA, Rasband WS, Ellicieri KW (2012) NIH image to ImageJ: 25 years of image analysis. Nat Methods 9:671–675

23. Lugli A, Kirsch R, Ajioka Y et al (2017) Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Med Pathol Off J U S Can Acad Pathol Inc 30:1299–1311. https://doi.org/10.1038/modpathol.2017.46

24. Martin B, Schäfer E, Jakubowicz E, Mayr P, Ihringer R, Anthuber M, Schenkirsch G, Schaller T, Märkl B (2018) Interobserver variability in the H&E-based assessment of tumor budding in pT3/4 colon cancer: does it affect the prognostic relevance? Virchows Arch Int J Pathol 473:189–197. https://doi.org/10.1007/s00428-018-2341-1
25. Smit M, van Pelt G, Roodvoets A, Meershoek-Klein Kranenburg E, Putter H, Tollenaar R, van Krieken J, Mesker W (2019) Uniform noting for international application of the tumor-stroma ratio as an easy diagnostic tool: protocol for a multicenter prospective cohort study. JMIR Res Protoc 8:e13464. https://doi.org/10.2196/13464

26. Märkl B (2015) Stage migration vs immunology: the lymph node count story in colon cancer. World J Gastroenterol 21:12218–12233. https://doi.org/10.3748/wjg.v21.i43.12218

27. Eriksen AC, Andersen JB, Lindebjerg J, dePont Christensen R, Hansen TF, Kjær-Frifeldt S, Sørensen FB (2018) Does heterogeneity matter in the estimation of tumour budding and tumour stroma ratio in colon cancer? Diagn Pathol 13:20. https://doi.org/10.1186/s13000-018-0697-9

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.